Connect your AI

Azenta AZTA Cash, Cash Equivalents, and Marketable Securities

Cash, Cash Equivalents, and Marketable Securities at other companies

Twist Bioscience CorporationTWST

$49M+4.9%

BioLife SolutionsBLFS

$57.93M+480%

Bio-Rad LaboratoriesBIO

——

Other financials

Income statement

Revenue$144.8M+1.0%

Gross profit$62.0M-1.2%

Operating income-$165.8M-811%

Net income-$160.8M-237%

EPS (diluted)-$3.49-236%

Balance sheet

Cash & equivalents$125.2M—

Total debt$55.7M—

Total equity$1.6B-8.3%

Total assets$1.9B—

Cash flow

Operating cash flow$13.5M-6.2%

CapEx$7.4M-0.1%

Free cash flow$6.1M-12.7%

Valuation

Market cap$1.1B-16.3%

Enterprise value$1.03B—

P/S1.8×-0.2×

Profitability

Gross margin40%-1.0pp

Operating margin-31.6%-59.7pp

Net margin-29.1%-80.7pp

FCF margin8.6%—

Returns & leverage

Return on equity-10.7%-22.4pp

Debt / equity0×—

Current ratio2.8×—

Where this comes from

Reported directly by Azenta in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.

The official record: Azenta’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Azenta's cash, cash equivalents, and marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Azenta's cash, cash equivalents, and marketable securities?: Azenta (AZTA) reported cash, cash equivalents, and marketable securities of $324.32M in Q1 2026.
What does cash, cash equivalents, and marketable securities mean?: This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.